Catalent, Inc. (CTLT)
USD 63.48
(0.0%)
USD 63.48
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 9.75 Billion USD | -9.54% |
| 2023 | 10.78 Billion USD | 2.62% |
| 2022 | 10.5 Billion USD | 15.31% |
| 2021 | 9.11 Billion USD | 17.17% |
| 2020 | 7.77 Billion USD | 25.75% |
| 2019 | 6.18 Billion USD | 36.48% |
| 2018 | 4.53 Billion USD | 31.17% |
| 2017 | 3.45 Billion USD | 11.75% |
| 2016 | 3.09 Billion USD | -1.73% |
| 2015 | 3.14 Billion USD | 1.79% |
| 2014 | 3.09 Billion USD | 1.09% |
| 2013 | 3.05 Billion USD | -2.62% |
| 2012 | 3.13 Billion USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 10.04 Billion USD | -6.83% |
| 2024 Q2 | 9.98 Billion USD | -0.58% |
| 2024 FY | 9.75 Billion USD | -9.54% |
| 2024 Q4 | 9.75 Billion USD | -1.28% |
| 2024 Q3 | 9.87 Billion USD | -1.09% |
| 2023 FY | 10.78 Billion USD | 2.62% |
| 2023 Q3 | 10.83 Billion USD | -2.84% |
| 2023 Q4 | 10.78 Billion USD | -0.44% |
| 2023 Q2 | 11.14 Billion USD | 9.23% |
| 2023 Q1 | 10.2 Billion USD | -2.88% |
| 2022 Q2 | 10.2 Billion USD | 0.2% |
| 2022 Q3 | 10.32 Billion USD | 1.17% |
| 2022 FY | 10.5 Billion USD | 15.31% |
| 2022 Q1 | 10.18 Billion USD | 11.75% |
| 2022 Q4 | 10.5 Billion USD | 1.8% |
| 2021 Q3 | 8.76 Billion USD | 6.97% |
| 2021 FY | 9.11 Billion USD | 17.17% |
| 2021 Q1 | 7.98 Billion USD | 2.67% |
| 2021 Q2 | 8.19 Billion USD | 2.68% |
| 2021 Q4 | 9.11 Billion USD | 3.91% |
| 2020 Q3 | 7.07 Billion USD | 14.27% |
| 2020 Q1 | 6.11 Billion USD | -1.04% |
| 2020 Q2 | 6.19 Billion USD | 1.24% |
| 2020 Q4 | 7.77 Billion USD | 9.84% |
| 2020 FY | 7.77 Billion USD | 25.75% |
| 2019 Q1 | 4.49 Billion USD | -0.69% |
| 2019 FY | 6.18 Billion USD | 36.48% |
| 2019 Q4 | 6.18 Billion USD | 37.63% |
| 2019 Q3 | 4.49 Billion USD | 1.16% |
| 2019 Q2 | 4.44 Billion USD | -1.29% |
| 2018 Q3 | 4.55 Billion USD | 3.81% |
| 2018 Q4 | 4.53 Billion USD | -0.51% |
| 2018 FY | 4.53 Billion USD | 31.17% |
| 2018 Q1 | 3.78 Billion USD | 9.57% |
| 2018 Q2 | 4.38 Billion USD | 15.91% |
| 2017 Q1 | 3.12 Billion USD | 1.2% |
| 2017 FY | 3.45 Billion USD | 11.75% |
| 2017 Q3 | 3.28 Billion USD | 4.15% |
| 2017 Q4 | 3.45 Billion USD | 5.15% |
| 2017 Q2 | 3.15 Billion USD | 0.84% |
| 2016 FY | 3.09 Billion USD | -1.73% |
| 2016 Q4 | 3.09 Billion USD | 1.09% |
| 2016 Q3 | 3.05 Billion USD | 0.74% |
| 2016 Q2 | 3.03 Billion USD | -0.69% |
| 2016 Q1 | 3.05 Billion USD | -2.83% |
| 2015 Q2 | 3.03 Billion USD | 2.94% |
| 2015 Q1 | 2.95 Billion USD | -4.49% |
| 2015 FY | 3.14 Billion USD | 1.79% |
| 2015 Q4 | 3.14 Billion USD | 5.76% |
| 2015 Q3 | 2.97 Billion USD | -2.11% |
| 2014 Q2 | 3.07 Billion USD | 1.03% |
| 2014 Q1 | 3.04 Billion USD | -0.5% |
| 2014 FY | 3.09 Billion USD | 1.09% |
| 2014 Q4 | 3.09 Billion USD | -0.03% |
| 2014 Q3 | 3.09 Billion USD | 0.59% |
| 2013 Q4 | 3.05 Billion USD | 0.0% |
| 2013 FY | 3.05 Billion USD | -2.62% |
| 2013 Q1 | - USD | 0.0% |
| 2012 FY | 3.13 Billion USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 3.47 Billion USD | -180.858% |
| Bausch Health Companies Inc. | 27.35 Billion USD | 64.34% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | -431.528% |
| Elanco Animal Health Incorporated | 14.36 Billion USD | 32.092% |
| Perrigo Company plc | 10.8 Billion USD | 9.77% |
| Teva Pharmaceutical Industries Limited | 43.47 Billion USD | 77.568% |
| Zoetis Inc. | 14.28 Billion USD | 31.73% |